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Objectives: We describe the development and validation of measures of human papillo-
mavirus (HPV)/HPV vaccination knowledge, fear/anxiety about vaccination, involvement in
HPV vaccine decision-making, and self-efficacy with regard to getting the vaccine,
designed to evaluate the efficacy of an intervention to affect these domains (collectively
termed the HAVIQ: HPV Adolescent Vaccine Intervention Questionnaire).
Study design: Literature search, cognitive interviews and cross-sectional survey.
Methods: A literature search identified existing items that were modified for the present
measures. Experts reviewed draft measures for face and content validity. Cognitive in-
terviews with adolescents were also used to assess content validity. Adolescents
completed the measures and an internal reliability analysis of each measure was
performed.
Results: The four experts concurred that the measures had face validity. Cognitive in-
terviews identified items requiring refinement. Content validity was examined with ten
experts and was deemed acceptable. There were 1800 adolescents who completed the
measures; Cronbach's alpha was >0.6 for three of the four measures. The four final mea-
sures are brief, comprising 25 items in total..
du.au (S.R. Skinner).
ic Health. Published by Elsevier Ltd. All rights reserved.
p u b l i c h e a l t h 1 4 7 ( 2 0 1 7 ) 7 7e8 378Conclusions: The measures are robustly developed and validity-tested. The HAVIQ may be
used in research settings to evaluate adolescents' knowledge and experiences of the pro-
cess of HPV vaccination in a school-based vaccination programme.
© 2017 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.Introduction
A national school-based programme in Australia offers the
human papillomavirus (HPV) vaccine to adolescent males and
females in the first year of secondary school (year seven or
eight, depending on jurisdiction, age 11e14 years), free-at-the-
point-of-receipt.1,2 A quadrivalent HPV vaccine is used in the
Australian programme (given in three doses at zero, one and
six months). This vaccine is designed to prevent infection and
disease caused by HPV types 6 and 11, which are responsible
for >90% of anogenital warts, and HPV genotypes 16 and 18,
which worldwide are responsible for approximately 50% of
precancerous lesions and 70% of cancerous lesions of the
cervix.3e5 HPV infections are also responsible for an
increasing subset of head and neck cancers.6 Three-dose
vaccination coverage for girls in Australia is relatively high,
at 73% for most recent estimates, with corresponding
coverage for males just over ten percentage points lower.7
These rates of vaccine coverage have resulted in impressive
reductions in HPV 16 and 18 prevalence8 and in high-grade
cytological lesions.9
In the Australian programme, the jurisdictional public
health authority responsible for implementation of the pro-
gramme provides a hard copy of a parent information
brochure and consent form (usually via the adolescent who is
given it to take home from school). In general, active parental
consent is required for vaccination. Previously no information
was provided to the adolescents themselves, with perhaps an
assumption that parents would convey appropriate informa-
tion to their adolescent. However, our previous research has
identified that parents do not often speak to their adolescent
about the HPV vaccine, for reasons of lack of confidence in
their own knowledge and feelings of embarrassment where
discussion might involve the sexually transmitted nature of
the virus.10e12 Our data have identified a lack of basic knowl-
edge and understanding among both adolescent girls and
their parents regardingHPV, the vaccine and cervical cancer.12
In 2014, as part of a Federal government health department
initiative, information resources for schools have been made
available via a website (www.hpv.gov.au). It is unclear how
well these resources have been taken up by schools, as yet, or
their impact on students. Indeed, our research has shown that
there have been challenges with effective inter-sectorial
collaboration between health and education government
sectors in the delivery of vaccination around issues pertaining
to the student experience in particular.13
Fear and anxiety regarding the vaccine has also been re-
ported, which may in part be attributed to this lack of knowl-
edge and the presence ofmyths and rumours.14,15 This fear andanxiety has been found to not only affect uptake16,17 but also
completion of the vaccine series.18 It also has a detrimental
effect on the vaccination process in schools, with individual
vaccinations taking longer while adolescents are calmed.14
There is some evidence that involving adolescents in the
decision to get the vaccine can affect uptake.19 Informed
decision-making can be empowered by education, whichmay
facilitate adolescents' having a voice in whether they get the
vaccine or not.20 We found that while some adolescents were
involved in this decision, a significant proportion were not.21
Shared decision-making was particularly hindered by
parent/adolescent discomfort with talking about sex together.
Australian girls have said that they would bemore involved in
the decision to be vaccinated if they were equipped with
knowledge about the vaccine.12
Theoretical models of health behaviour suggest a role for
self-efficacy (one's belief in one's ability to perform a certain
behaviour, akin to perceived behavioural control) in explain-
ing why individuals do or do not engage in health behaviours
and these models have been applied in the context of HPV
vaccination.22 We hypothesised that self-efficacy to be
involved in the decision-making process would be predictive
of actual involvement in the decision and expressed anxiety
and fear. Therefore we also considered self-efficacy to be an
important concept to consider.
On the strength of these data and reasoning, we developed
an educational intervention for adolescents aged 11e14
years, due to be offered HPV vaccination (as part of a larger
intervention also targeting parents and vaccination pro-
gramme organisational issues),20,23 that aimed to effect
change in four domains hypothesised to be related to student
experience of vaccination and vaccination uptake: (1)
knowledge about HPV and the HPV vaccine; (2) adolescents'
involvement in the decision-making process; (3) fear and
anxiety associated with the vaccine; and (4) self-efficacy in
receiving the vaccine.20 It is necessary to have a robust
measure of these domains to evaluate the efficacy of in-
terventions, such as our own, designed to change these do-
mains. A literature review identified that past research had
used items similar to those required for use. However, no
scale fully met our needs: a brief measure, validated for use
with young adolescents (aged 11e14 years) that could be
practically administered within the context of a mass school
vaccination programme before and after the educational
intervention and acceptable to all types of school. In this
paper we describe the development and validation of four
short measures designed to detect change in these domains,
known collectively as the HPV Adolescents Vaccination
Intervention Questionnaire (HAVIQ).
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The development and validation of the measures occurred in
a number of stages: item identification, measure development
and assessment of face validity, content validity and internal
reliability. Item identification and scale development are
described in full in this methods section, with the results of
the validation and reliability analyses reported in the Results
section.
Item identification
We identified potential items and existing measures of each
domain in the context of HPV vaccination, as well as other
preventive health behaviours, from a detailed desk-based
rapid review of the literature. Existing items were modified
or items created for the present measures.
Knowledge
Verymany studies havemeasured knowledge or awareness of
HPV/HPV vaccination (e.g.24e27). There were appropriate
questions in all of these studies that could have been used in
the knowledge measure, but the question content was most
comprehensively covered in a well-developed scale for adults
that was being validated at the time of this research.28 We
therefore based the majority of the items on that scale.
Self-efficacy
Two studies were identified that measured self-efficacy in the
context of getting the HPV vaccine25,26 and two items from
these studies were adapted for our self-efficacy measure. A
number of other studies addressed self-efficacy in relation to
other preventive health behaviours. One study in particular
examining the psychometric properties of the Self-Efficacy
Questionnaire for Children included items that were rele-
vant for adolescents29 and two of thesewere rephrased so that
they were appropriate for our self-efficacy measure. We also
rephrased five items that were psychometrically tested in
phobic situations.30 One final item was rephrased from the
Measurement of Self-Efficacy and Externality scale so that it
was relevant to HPV vaccination.31
Fear and anxiety
Two studies were found that sought to assess fear and/or
anxiety in relation to HPV vaccination. One study used ques-
tions to evaluate general feelings towards needles26 and two
items from this study were adapted for our fear and anxiety
measure. Another study sought to assess girls' psychological
response to a leaflet containing information about HPV
infection and vaccination.24 These authors used a short six-
point form of the Spielberger State Trait Anxiety Inventory
(STAI) which has been previously assessed and found to
generate results that were comparable to using the full form of
the STAI.32 The short version of the STAI was used as a basis
for formulating HPV vaccine-specific items.
Involvement in decision-making
We were aware of a study, at the time unpublished33 that
measured HPV vaccination decision-making in universitystudents. We rephrased several items from this study so that
they were suitable for adolescents in a school-based setting.
Other itemswere generated by the research teambased on the
findings of two studies that had considered factors that were
deemed relevant to involvement in decision-making.26,34
Measure development
Using the items identified in the literature review, we collec-
tively drafted a preliminary version of the measures. Existing
items sourced from the literature were reworded where
necessary and, where gaps in the domains to be measured
were identified, new items were developed by the research
team to ensure that all facets of the intervention were
covered. There were 37 questions in the initial item pool, 15 of
which were developed by the research team. We ensured that
the measures were of an appropriate reading level for our
intended participants (11e14 year old adolescents) by con-
ducting a readability assessment with Flesch's statistic in
Microsoft Word. All items were checked by the research team
for ambiguity, use of jargon and length and double barrelled
questions avoided as they can be difficult to answer with a
single response.35 Itemswereworded in either direction of the
domain being measured to preclude generalised responses to
the items, as this can limit validity.36,37
Likert-type scale response categories were used for the
involvement in decision-making and fear/anxiety measures
as dichotomous ‘yes’/‘no’ responses can result in a loss of
information35 and can restrict respondents' answers.38 Five to
nine response categories are usually recommended for Likert
scales,35 so a five-point scale was used with the options
‘strongly disagree’, ‘disagree’, ‘neither agree nor disagree’,
‘agree’ and ‘strongly agree’. For the knowledge measure, we
opted for a five-point scale.
It is recommended that self-efficacy is measured with a
100-point scale, with participants choosing a number to
indicate how confident they are (one being ‘not confident at
all’ and 100 being ‘completely confident’).39 However, we also
considered that a shorter (five-point) Likert-type scale could
be simpler to complete as it would be consistent with the
othermeasures.We opted to test both response scales for ease
of use.
Assessment of face validity
The draft HAVIQwas reviewed by four international experts in
the field of school-based HPV vaccine delivery and psycho-
social aspects of uptake to check for possible omissions.
Recommendations for improvement were also sought.
Assessment of content validity
Cognitive interviews with adolescents
We conducted cognitive interviews with adolescent females,
aged 12 and 13 years old to ascertain whether there were
problems with any items, to understand their thoughts on the
measures in general and whether they had any suggestions
for improvements. These interviews were conducted prior to
HPV vaccination being offered to boys in Australia. A further
function was to test the appropriateness of the response
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with secondwave participants commenting on items that had
been revised as a result of the first wave of cognitive in-
terviews. Girls were recruited through informal networks,
with cognitive interviews conducted at the girls' homes and
with both parents and adolescents providing informed con-
sent. Approval for these interviews was obtained from the
Children's Hospital at Westmead Research Ethics Committee.
Expert review
Following the cognitive interviews, we conducted another
expert review as an additional measure of content validity.
The aim of the expert reviewwas to assess if the items in each
measure were relevant and whether the four measures were
adequately represented by the selected items.40,41 Ten na-
tional/international experts with expertise in HPV vaccination
(including paediatricians, psychologists, epidemiologists, a
nurse and a general practitioner) were asked to rate each item
as being ‘essential’, ‘useful but not essential’ or ‘not neces-
sary’ as well as provide any comments on eachmeasure. Four
of these experts had previously commented on the face val-
idity of the measures.
Content validity was calculated using Lawshe's formula.42
Lawshe proposes that each expert's ‘essential’ rating be used
to calculate the level of agreement for each item's inclusion
resulting in a content validity ratio (CVR) for each measure.
The formula for this is: CVR¼ (ne  N/2)/(N/2) with ne being the
number of ‘essential’ ratings per item and N being the number
of expert panellists. CVR greater than 0.62 for ten experts is
considered acceptable.
Assessment of internal reliability
Internal reliability was assessed by asking adolescents to
complete the HAVIQ. Adolescents were recruited as part of a
large randomised controlled trial. Recruitment methods have
been described fully elsewhere.23 In brief, participants were
male and female adolescents in their first or second year of
high school (year 8 or 9) who were due to be offered the HPV
vaccine as part of the school-based programme. The study
obtained full ethical approval from Western Australia's
Department of Health Human Research Ethics Committee and
South Australia's Women's and Children's Hospital Human
Research Ethics Committee. Participants were adolescents
recruited from the 19 schools in the control arm of the trial; a
stratified random sample of 40 schools across two Australian
States.23 Schools were diverse in type (co-educational/single
sex and independent, government and catholic schools).
Students completed the HAVIQ in school prior to being offered
HPV vaccination. Cronbach's alphas were calculated for each
measure using SPSS, along with an item-correlation matrix
and Cronbach's alphas if items were to be deleted from each
measure.Table 1 e Content validity index: progressive analyses.
Analysis stage Knowledge Self-
efficacy
Fear and
anxiety
Decision-
making
First 0.40 0.04 0.42 0.38
Final 0.87 0.72 0.67 0.63Results
We began development of the HAVIQ in 2010 and completed
face and content validity assessments in 2011. Reliability was
completed in early 2016, with data collected in 2013 and 2014.The preliminary version of the HAVIQ had a Flesch's reading
score of 66.1 and a Flesch-Kincaid grade level of 6.2, indicating
that it was suitable for adolescents of our targeted age group.
Face validity
All four experts concurred that the measures should effec-
tively capture any changes in knowledge, fear/anxiety and
self-efficacy and would also quantify adolescents' involve-
ment in the decision-making process.
Content validitydcognitive interviews
Several suggestions made by adolescents during cognitive
interviews (n ¼ 5, all female) included simplifying items by
removing words and rewording questions. One example of
this was to change the item ‘HPV can be caught by engaging in
sexual activity’ to ‘HPV can be caught through sexual activity’.
Sometimes adolescents answered items by considering
what their peers might think, rather than answering specif-
ically about their beliefs. We adjusted items to clarify this (i.e.
‘having to get a needle can be upsetting’ was extended to
‘having a needle can be upsetting to me’).
Four out of the five adolescents preferred the 100-point
self-efficacy response option because it allowed them to be
more accurate, said that it ‘mademore sense andwas easier to
understand’ and was ‘more like a percentage’ (which is used
by their teachers when marking exams).
The measure underwent further cognitive interviewing
with two adolescents to check the modifications made
following the first round of cognitive interviews. Three items
were removed as a result of the second round of interviews as
their revised wording meant that the items had lost their
meaning or were ambiguous.
Content validitydexpert review
Initial calculations fromour expert panel (n¼ 10) revealed that
the content validity index (CVI) was low for each measure
(Table 1), none of which met the minimum CVI of 0.62 that is
required for the ratings of 10 experts.
We therefore examined questions with a particularly low
number of essential ratings and thus a low CVR, to establish
whether they could be discarded to improve the overall CVI of
each measure. The CVIs for each measure were then recal-
culated in a second analysis after dropping several items,
including five items from the decision-makingmeasure, three
from the knowledge measure, five from the self-efficacy
measure and four from the fear/anxiety measure. This
improved the measures of CVIs so that all were greater than
the minimum requirements for content validity (Table 1).
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rently reviewed. On the whole, feedback was positive, with
few suggestions for improvements or rewording to the items.
Unsurprisingly, the majority of comments related to items
that were removed during the CVI analysis stage.
Internal reliability
The HAVIQ was completed by 1800 male (n ¼ 982) and female
(n ¼ 817) adolescents (1 ¼ gender unknown). For the fear/
anxiety and involvement in decision-making measures,
‘strongly disagree’ responses were scored 1, through to 5 for
‘strongly agree’. With hindsight the study team decided that
knowledge should have been measured using the response
options ‘true’, ‘false’ or ‘don't know’. For this reason, we
recoded the knowledgemeasure response options as ‘strongly
disagree/disagree’, ‘neither agree nor disagree’ and ‘strongly
agree/agree’, as proxy measures of ‘true’, ‘false’ and ‘don't
know’. For example, for the question ‘HPV is very rare’, the
responses ‘strongly disagree’ and ‘disagree’ were akin to
‘true’. Each self-efficacy item was scored out of 100. For each
measure, item totals were summed to give a measure total.
The Cronbach's alphas for the knowledge measure
(alpha ¼ 0.60), fear/anxiety measure (alpha ¼ 0.79) and self-
efficacy measure (alpha ¼ 0.79) were acceptable. Item total
statistics suggested that the deletion of items from these three
measures would not remarkably alter the Cronbach's alpha;
item correlation was adequate and not indicative of multi-
collinearity. The alpha for the involvement in decision-
making measure was poor (alpha ¼ 0.35), however item cor-
relation was good with no evidence of multicollinearity and
removing items would not improve the Cronbach's alpha.
The final measure
The final HAVIQ, comprises 25-items assessing adolescents'
knowledge about HPV/HPV vaccination, their involvement in
the vaccine decision-making process and their fear/anxiety
and self-efficacy with regard to the vaccine with four separate
measures (see Supplementary Material for the measure).Discussion
This measure of adolescents' knowledge about HPV/HPV
vaccination, their involvement in the vaccine decision-
making process and their fear/anxiety and self-efficacy with
regard to the vaccine was deemed to have face and content
validity, and three of the four measures had acceptable in-
ternal reliability. The HAVIQ has been used to assess the ef-
ficacy of a school-based intervention aiming to maximise
uptake of HPV vaccination,20,23 with the separate measures
having specific research applications in the evaluation of ad-
olescents' knowledge and experiences of the process of HPV
vaccination in a school-based vaccination programme.
An understanding about the transmission of HPV aswell as
the development of anogenital warts, and HPV-related can-
cers is particularly pertinent to adolescents, given that they
are vulnerable to HPV infection and subsequently at risk for
cervical, anal, penile, vulvar, vaginal, oropharyngeal cancersand anogenital warts.43e45 Knowledge about the HPV vaccine,
HPV virus and its relationship with these cancers and ano-
genital warts is considered fundamental in ensuring informed
vaccination decision-making.46e48 Evidence suggests that
improved knowledge may facilitate increased adolescent
involvement in immunisation decisions, reduce fear about
getting vaccines, increase the likelihood that vaccination de-
cisions are informed and their attitudes to vaccination are
favourable.12,14,15,20 It is important to be able to measure these
domains in adolescents so that interventions to improve such
domains can be evaluated. The four separate measures
developed in this paper have research applications in the
evaluation of adolescents' knowledge and experiences of the
process of HPV vaccination in a school-based vaccination
programme.
The study is not without limitations. The cognitive in-
terviews were conducted with a limited number of interested
adolescents, so their perceptions of the measure items may
not reflect those of a more general population of adolescents.
The decision-making measure did not have an acceptable
level of internal reliability suggesting this measure could
benefit from further modification or the individual items
considered separately. However, the international experts
concurred that the HAVIQ should assess what it was aiming
to. With hindsight we would also recommend rewording the
knowledge measure response options to ‘true’, ‘false’ and
‘don't know’. Since the development of this measure, an
alternative scale measuring HPV knowledge in adults has
been published, so other approaches to assessing knowledge
may be considered.28 It would be useful to conduct a test-
retest reliability of the measures. Although participants who
completed the HAVIQ for the internal reliability analysis also
completed the HAVIQ at additional time points, it was not
possible to test responsiveness as participants would have
been offered the HPV vaccine between data collection time
points, so onemight have expected their responses to change.
However, to our knowledge, the HAVIQ is the only group of
measures, designed specifically for young adolescents being
offered HPV vaccination in a school programme and tested in
this age group.
The HAVIQ is a robustly developed and psychometrically
tested set of measures of adolescents' knowledge about HPV/
HPV vaccination, involvement in vaccine decision-making
and their fear/anxiety and self-efficacy with regard to the
vaccine. The HAVIQ is designed to evaluate the efficacy of a
HPV educational intervention designed to effect change in
adolescents' knowledge and experiences of the process of HPV
vaccination in a school-based vaccination programme, but
could be used to evaluate interventions aimed at improving
any of these domains among adolescents.Author statements
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